Request Demo

Last update 01 Sep 2026

Treprostinil

Last update 01 Sep 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dry powder formulation of treprostinil(MannKind Corporation), TETON, TREPROSTINIL

+ [22]

Target

PGI2 receptor

Action

agonists

Mechanism

PGI2 receptor agonists(Prostanoid IP receptor agonists)

Therapeutic Areas

Respiratory DiseasesOther DiseasesImmune System Diseases+ [8]

Active Indication

Hypertension, PulmonaryLung Diseases, InterstitialChronic thromboembolic pulmonary hypertension+ [13]

Inactive Indication

Anemia, Sickle CellChronic Limb-Threatening IschemiaCombined pulmonary fibrosis and emphysema+ [10]

Originator Organization

United Therapeutics Corp.

Active Organization

United Therapeutics Corp.

AOP Orphan Pharmaceuticals GmbH

Camurus AB

+ [10]

Inactive Organization

Lee's Pharmaceutical Holdings Ltd.

MannKind Corp.

License Organization

Liquidia Corp.

Mochida Pharmaceutical Co., Ltd.

Pharmosa Biopharm, Inc.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (21 May 2002),

Pulmonary Arterial Hypertension

RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea)

Structure/Sequence

Molecular FormulaC23H34NaO5

InChIKeyRCKWZOAISRYANP-ZSESPEEFSA-N

CAS Registry289480-64-4

110

Clinical Trials associated with Treprostinil

NCT07748000

/ Not yet recruitingPhase 2

A Phase 2a Randomized, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of LIQ861 in Participants With Systemic Sclerosis Experiencing Symptomatic Raynaud's Phenomenon Attacks / RE-WARM

Systemic sclerosis (SSc) is a rare autoimmune disease in which many patients experience Raynaud's phenomenon (RP) - painful episodes where commonly fingers or toes change color and become painful, numb, or tingly, usually triggered by cold or stress. This open-label study is testing an inhaled powder form of treprostinil (LIQ861) to find out which doses can be taken safely and comfortably by adults with SSc who have frequent symptomatic RP attacks. About 75 adults will be randomly assigned (2 to 1) to either a dose-titration group or a fixed low-dose group. The study also explores whether treatment reduces the number, severity, and impact of RP attacks. The main goal is to identify tolerated dose(s).

Start Date26 Oct 2026

Sponsor / Collaborator

Liquidia Technologies, Inc.

NCT07759804

/ Not yet recruitingPhase 4

An Open-label Study to Evaluate the Safety and Tolerability of LIQ861 in Participants With WHO Group 1 PAH Transitioning From Oral Selexipag to Inhaled Treprostinil

This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a medicine breathed into the lungs.
Everyone who takes part will receive LIQ861. On the first study day, participants will stop taking selexipag and begin taking LIQ861 four times a day using a small handheld dry powder inhaler. The dose may be increased over time based on how well it is tolerated. Participants will take LIQ861 for 16 weeks.
The study will also look at whether switching to LIQ861 affects walking distance, a blood marker of heart strain, and symptoms reported by participants.

Start Date01 Sep 2026

Sponsor / Collaborator

Liquidia Technologies, Inc.

NCT07736846

/ Not yet recruitingNot Applicable

Multicenter Registry Evaluating Real-World Therapeutic Patterns and Outcomes in Newly Diagnosed Adult Patients With Pulmonary Arterial Hypertension (PAH) Treated With Parenteral Treprostinil

TRESPECT is an international, multicenter, observational registry designed to describe the real-world use, effectiveness, and tolerability of parenteral treprostinil in adults with newly diagnosed pulmonary arterial hypertension (PAH). The registry will include patients who initiated subcutaneous or intravenous treprostinil within 12 months of PAH diagnosis.
Both retrospective and prospective data will be collected from routine clinical care. Data will include patient characteristics, PAH treatment patterns, treprostinil dosing and route of administration, functional status, exercise capacity, biomarkers, echocardiographic and hemodynamic parameters, clinical events, and adverse events. Participants will be followed for at least 36 months or until a registry termination criterion is met. The registry is expected to enroll approximately 100 to 300 patients across specialized PAH centers in several European countries.

Start Date01 Jul 2026

Sponsor / Collaborator

AOP Orphan Pharmaceuticals GmbH

100 Clinical Results associated with Treprostinil

100 Translational Medicine associated with Treprostinil

100 Patents (Medical) associated with Treprostinil

914

Literatures (Medical) associated with Treprostinil

01 Oct 2026·PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS

Cardiovascular safety profile of prostaglandin E and prostacyclin analogues: Clinical reports and ex vivo studies on human coronary arteries

Review

Author: Moude, Izza ; Senbel, Amira ; Para, Marylou ; Norel, Xavier ; Abdelazeem, Heba ; Longrois, Dan ; Badji, Hichem ; Deschamps, Lydia ; Li, Zhipeng ; Merheb, Gaelle ; Abifadel, Marianne

Prostaglandin E₁ (PGE₁), prostaglandin E₂ (PGE₂), prostacyclin and their analogues are widely used in clinical practice for their potent biological effects. PGE₁/PGE₂ analogues, including misoprostol and sulprostone, are primarily used in obstetrics for labour induction, abortion, and postpartum haemorrhage management, whereas PGI₂ analogues such as iloprost and treprostinil are key drugs in pulmonary arterial hypertension treatment. Despite structural similarities, these compounds produce contrasting vascular effects due to differences in receptor selectivity, signalling pathways, and tissue distribution. PGE₁/PGE₂ analogues activate EP receptors, particularly EP1 and EP3 with varying selectivity profile, promoting vasoconstriction and have been associated with cardiovascular complications such as coronary vasospasm. In contrast, PGI₂ analogues act mainly on IP receptors, promoting vasodilation, inhibition of platelet aggregation, and beneficial vascular remodelling, with a generally favourable cardiovascular safety profile. Although cardiovascular effects have been reported with both classes of analogues, the underlying mechanisms, and especially their direct effects on human coronary arteries (HCA) remain insufficiently explored. In this context, we combined a review of the clinical and experimental literature that integrates clinical reports with original ex vivo pharmacological investigations on isolated HCA. Both PGE₂ and misoprostol induce concentration-dependent vasoconstriction, primarily via EP3 receptors, which is significantly reduced by a TP receptor antagonist, suggesting a potential EP3-TP pathway interaction. All tested PGI₂ analogues consistently induced relaxation in our HCA preparations, a finding that aligns with their general improvement of cardiovascular clinical parameters, with only rare exceptions. Together, these findings summarize the cardiovascular effects of clinically-used prostanoids and provide mechanistic insights to optimize their therapeutic use while minimizing cardiovascular risk.

01 Aug 2026·CURRENT PROBLEMS IN CARDIOLOGY

Management of pulmonary arterial hypertension with intermediate-high-risk pulmonary embolism during pregnancy: Diagnostic challenges, catheter-directed thrombolysis, and intravenous treprostinil — A narrative review with an institutional case snapshot

Review

Author: Navarro-Vergara, Dulce-Iliana ; Torres-Rojas, María-Berenice ; Hernandez-Villa, Lizbeth ; Roldan-Valadez, Ernesto ; Cueto-Robledo, Guillermo ; Ruiz-Domínguez, Daniel ; García-Cesar, Marisol

BACKGROUND:

Maternal mortality from pregnancy-related pulmonary arterial hypertension (PAH) is estimated at 7-12%. The superimposition of pulmonary embolism (PE) and COVID-19 further compromises right-ventricular (RV) function. Pregnancy-compatible PAH pharmacotherapy and catheter-directed techniques show promise; however, their intersection remains undocumented.

METHODS:

We performed a narrative review of imaging diagnosis, risk stratification, catheter-directed reperfusion, PAH-targeted pharmacotherapy, and multidisciplinary peripartum management of PAH complicated by acute PE during pregnancy. MEDLINE/PubMed, Embase, Scopus, and the Cochrane Library were searched up to March 2026. We also describe an institutional case from the Hospital General de México Dr. Eduardo Liceaga (Mexico City, Mexico).

RESULTS:

Evidence supports echocardiography for initial assessment, CT pulmonary angiography for embolic/vascular evaluation, right-heart catheterization for hemodynamic determination, and catheter-directed thrombolysis for intermediate-high-risk PE when systemic thrombolysis is contraindicated. The institutional case describes a 17-year-old primigravida (24.6 weeks' gestation) with undiagnosed idiopathic PAH (mean pulmonary artery pressure 64 mmHg; pulmonary vascular resistance (PVR) 13.8 Wood units), intermediate-high-risk PE (thrombotic burden 37.5%), and COVID-19 pneumonia. Catheter-directed thrombolysis combined with sildenafil and intravenous treprostinil achieved substantial hemodynamic improvement (cardiac index 2.8 to 4.2 L/min/m²; PVR 13.8 to 6.7 Wood units). Elective cesarean at 37 weeks resulted in satisfactory maternal and neonatal outcomes.

CONCLUSIONS:

Early, multidisciplinary approaches integrating invasive hemodynamics, catheter-directed thrombolysis, and pregnancy-compatible PAH therapy can decompress RV function and allow safe pregnancy continuation. Prospective international registries and pregnancy-specific PERT pathways are urgently needed.

15 Jul 2026·CLINICAL SCIENCE

IL-22BP attenuates right ventricular remodeling in pulmonary arterial hypertension

Article

Author: Liu, Zhengxia ; Lu, Chen ; Zeng, Wei ; Zhou, Ping ; Zhang, Juan ; Yang, Jiahui ; Liu, Ying ; Hu, Wenhui ; He, Wei ; Feng, Han ; Qu, Chen ; Tao, Xinyu ; Zou, Jiahui

Abstract:

Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary disease in which right ventricular (RV) dysfunction and remodeling are major determinants of poor prognosis. Interleukin-22 binding protein (IL-22BP), encoded by IL22RA2/Il22ra2, is an endogenous antagonist of IL-22, but its role in PAH-associated RV remodeling remains unclear. Here, we investigated whether IL-22BP regulates RV remodeling through the IL-22/STAT3 axis. Serum IL-22BP levels were reduced in patients with PAH. In experimental PAH, RV IL-22BP was decreased in Sugen5416/hypoxia (SuHx) and monocrotaline rat models, and both RV Il22ra2 mRNA and IL-22BP protein were reduced in SuHx mice. In the SuHx mouse model, systemic Il22ra2 deficiency aggravated PAH severity and RV remodeling, accompanied by enhanced RV IL-22/IL-22R1/STAT3 signaling and increased remodeling-associated transcripts related to hypertrophy, fibrosis, apoptosis, and proliferation. Conversely, AAV-mediated IL-22BP reconstitution with preferential cardiac expression attenuated RV hypertrophy and dysfunction and suppressed RV IL-22/STAT3 signaling. Pharmacological STAT3 inhibition with S3I-201 partially rescued the aggravated PAH and RV remodeling phenotype in SuHx-treated Il22ra2−/− mice. Complementary H9C2 cell experiments showed that IL-22 enhanced Ang II-associated STAT3 activation and remodeling-related transcriptional responses, whereas S3I-201 attenuated several Ang II-induced remodeling signals. Lung analysis showed altered pulmonary IL-22/STAT3 signaling after SuHx exposure and Il22ra2 deficiency, but cardiac IL-22BP reconstitution did not significantly normalize these whole-lung markers. Th17-related immune changes paralleled disease severity and IL-22BP-associated improvement. Finally, treprostinil plus oridonin produced broader phenotypic improvement than either monotherapy and increased cardiac IL-22BP expression. These findings identify IL-22BP as a treatment-responsive endogenous regulator of PAH-associated RV remodeling.

237

News (Medical) associated with Treprostinil

01 Sep 2026

·www.biospace.com

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension ( PAH ) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis ( IPF ) patients Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and preliminary data from PHINDER , a first of its kind study designed to improve screening for pulmonary hypertension associated with interstitial lung disease ( PH-ILD ) SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology ( ESC ) Congress 2026, August 28-31 in Munich, and at the European Respiratory Society ( ERS ) Congress 2026, September 5-9 in Barcelona. The presentations include late-breaking analyses from the phase 3 ADVANCE OUTCOMES study of investigational ralinepag in PAH, the phase 3 TETON clinical program evaluating nebulized treprostinil in IPF, and the ARTISAN study evaluating parenteral treprostinil in PAH, as well as preliminary data from the PHINDER study in PH-ILD. “This year at ERS and ESC, we are presenting data that reflect the breadth of our work to deepen our understanding of how appropriate treatment may improve outcomes for people living with life-threatening diseases like PAH, PH-ILD, and IPF. We remain committed to generating meaningful evidence across both established and investigational therapies to help advance the standard of care for these patient populations,” said Franck Rahaghi, M.D. , Chief Medical Officer, United Therapeutics. ESC oral presentations Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE OUTCOMES Study Late-breaking Oral Presentation, Saturday, August 29, 11:00 - 11:15 AM CEST. Presented by George Giannakoulas, M.D., Ph.D., Thessaloniki, Greece. Early and Rapid Treprostinil Titration Improves Right Ventricular Ejection Fraction at 12 Months in Pulmonary Arterial Hypertension: ARTISAN Interim Analysis Late-breaking Oral Presentation, Saturday, August 29, 12:00 - 12:15 PM CEST. Presented by Irene Marthe Lang, M.D., Vienna, Austria. ERS oral and poster presentations The Effect of Inhaled Treprostinil in Patients with Idiopathic Pulmonary Fibrosis Using a Win Ratio Analysis Late-breaking Poster, PS-34, Abstract #PA824, Sunday, September 6, 8:00 - 9:30 AM CEST. Presented by Vincent Cottin, M.D., Ph.D., Lyon, France. ARTISAN Interim Analysis: Early High-Dose Treprostinil Reduces mPAP and Improves Pulmonary Arterial Hypertension Risk Profile Poster, PS-38, Abstract #PA910, Sunday, September 6, 8:00 - 9:30 AM CEST. Presented by Prof. Carmine Dario Vizza, Roma (RM), Italy. Effect of Inhaled Treprostinil Dosing in Patients with Idiopathic Pulmonary Fibrosis Enrolled in the TETON IPF Program Poster, PS-34, Abstract #PA833, Sunday, September 6, 8:00 - 9:30 AM CEST. Presented by Vincent Cottin, M.D., Ph.D., Lyon, France. Clinical Improvement with Ralinepag in a Contemporary Pulmonary Arterial Hypertension Population: Insights from the ADVANCE OUTCOMES Study Late-breaking Oral Presentation, 3K, Abstract #OA1218, Sunday, September 6, 9:30 – 10:45 AM CEST. Presented by Prof. Marc Humbert, M.D., Ph.D., Le Kremlin-Bicêtre, France. Improvements in Lung Function Among Idiopathic Pulmonary Fibrosis Patients Treated with Inhaled Treprostinil Oral Presentation, 3K, Abstract #OA3523, Monday, September 7, 11:00 AM - 12:15 PM CEST. Presented by Juergen Behr, Prof. Dr. med. München, Germany. Limitations of Echocardiography for Pulmonary Hypertension Screening in Interstitial Lung Disease: Interim Results from the PHINDER Study Poster, PS-37, Abstract #PA6317, Tuesday, September 8, 12:30 - 2:00 PM CEST. Presented by C.M. Thrasher, Pharm.D., M.A., Research Triangle Park, United States. In June 2026, United Therapeutics submitted a New Drug Application for ralinepag to treat PAH, and a supplemental New Drug Application for nebulized treprostinil to treat IPF, to the FDA. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Nebulized treprostinil remains investigational for IPF. About United Therapeutics Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at and follow us on LinkedIn , Facebook , and Instagram . Forward-Looking Statements Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others: our plans to generate meaningful evidence across both established and investigational therapies to help advance the standard of care for people living with life-threatening diseases like PAH, PH-ILD, and IPF; and our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of August 28, 2026, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. Contacts Investor Inquiries Media Inquiries communications@unither.com

Phase 3Clinical Result

24 Aug 2026

·allsci.com

FDA accepts United Therapeutics' ralinepag NDA for PAH

The US FDA has accepted for review a New Drug Application from United Therapeutics Corporation (Nasdaq: UTHR) for ralinepag, an investigational prostacyclin IP receptor agonist intended to treat pulmonary arterial hypertension (PAH). The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027. The filing rests on results from the Phase III ADVANCE OUTCOMES study, in which ralinepag reduced the risk of a first clinical worsening event by 55% compared with placebo (hazard ratio 0.45, 95% CI [0.33–0.62]; p<0.0001) in 687 predominantly pre-treated patients. The trial population was notable for its relatively preserved baseline functional status — 70% of patients were World Health Organization Functional Class (WHO FC) II and 80% were on dual background therapy. Ralinepag also demonstrated statistically significant improvements in N-terminal pro-B-type natriuretic peptide (NT-proBNP; 24.3% reduction over placebo; p=0.0013) and six-minute walk distance (6MWD; +20.4 m placebo-corrected difference; p=0.0033), and increased the odds of clinical improvement by 47% (p=0.015). The full results were published in The Lancet in July 2026. The safety profile was consistent with known prostacyclin-related adverse events — primarily headache, diarrhea, nausea, and myalgia — and the company said no new safety signals were observed. United states that ralinepag would be the first once-daily oral prostacyclin IP receptor agonist available for PAH if approved. The current oral options in the prostacyclin class are selexipag (Uptravi), which requires twice-daily dosing, and oral treprostinil (Orenitram), which requires multiple daily doses taken with food. Merck's sotatercept (Winrevair), approved in 2024 via a distinct activin signaling mechanism, has added a new layer of competition in the class, but does not directly overlap with the prostacyclin pathway. In May 2026, the company and MannKind Corporation (Nasdaq: MNKD) announced development of a dry powder inhalation formulation of ralinepag (MNKD-1501) for PAH and fibrotic lung diseases, with MannKind eligible for up to USD 35 million in development milestones. United said it plans to file an investigational new drug application for ralinepag DPI later in 2026. Spot something wrong? Report an issue with this article

Phase 3NDADrug ApprovalClinical ResultIND

24 Aug 2026

·www.biopharmadive.com

FDA extends review of Capricor cell therapy; Pain drug startup to go public

Today, a brief rundown of news involving Capricor Therapeutics and GSK, as well as updates from Ambros Therapeutics and United Therapeutics that you may have missed.The Food and Drug Administration has extended its review of an experimental Duchenne muscular dystrophy cell therapy from Capricor Therapeutics. The agency had an Aug. 22 deadline to decide whether to approve Capricors deramiocel for a deadly heart-related complication of Duchenne. But as its CEO told investors earlier this month, Capricor updated its application with follow-up data that can support a refined indication focused on upper limb function. The FDA deemed that information a major amendment and delayed its decision by three months. Itll now issue a verdict by Nov. 22. An advisory panel voted against deramiocel in cardiomyopathy, but expressed more support for Capricors findings on upper limb function.GSK has won the first clearance of a hepatitis B drug it sees as a blockbuster-to-be. Drug regulators in Japan on Monday approved Hibsago, an antisense oligonucleotide therapy GSK and partner Ionis Pharmaceuticals developed for chronic hepatitis B infections. GSK and Ionis are positioning Hibsago as a functional cure for these persistent infections, as the drug has shown the potential in clinical testing to push the virus down to undetectable levels in six months. Regulatory decisions are expected in multiple geographies, including the U.S., in the coming months, according to GSK. The drug is one of 15 the company has highlighted as likely to generate more than $2 billion in peak sales in the years ahead.Pain medicine developer Ambros Therapeutics will go public through a reverse merger with cash-strapped biotechnology firm Werewolf Therapeutics. The drugmakers on Friday announced a deal though which Ambros stockholders will end up with 71.7% of the combined company and Werewolf shareholders will have a 6.8% stake. Investors participating in a concurrent $150 million offering, meanwhile, will gain a 21.5% ownership position. Co-founded by biotech entrepreneur and former presidential candidate Vivek Ramaswamy, Ambros is developing a medication for complex regional pain syndrome Type I, a rare and chronic condition with no FDA-approved treatments. That prospect, “neridronate,“ is in late-stage testing. Cancer-focused Werewolf, meanwhile, laid off the majority of its staff earlier this year and sought strategic alternatives after running short on cash.U.S. regulators have begun reviewing a new blood pressure medication from United Therapeutics. According to United, the FDA accepted an application for the pulmonary arterial hypertension drug ralinepag and should make a decision by June 24, 2027. Ralinepag is a newer type of prostacyclin receptor agonist, a therapy designed to help widen blood vessels in people with the condition. United acquired it in a 2018 licensing deal with Arena Pharmaceuticals and, in late-stage testing, the treatment lowered the risk of patients disease worsening by 55% when compared to a placebo. Ralinepag's potential approval is one of two coming launches into multibillion-dollar markets for United next year, Leerink Partners analyst Roanna Ruiz wrote in a recent research note. The company's also seeking clearance to use another PAH drug, Tyvaso, to treat people with idiopathic pulmonary fibrosis. '

Drug ApprovalLicense out/inOligonucleotide

100 Deals associated with Treprostinil

External Link

KEGG	Wiki	ATC	Drug Bank
D06213 D08628	Treprostinil	B01AC21	DB00374

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension, Pulmonary	United States	United Therapeutics Corp.	23 May 2022
Lung Diseases, Interstitial	United States	United Therapeutics Corp.	31 Mar 2021
Chronic thromboembolic pulmonary hypertension	European Union	SciPharm SARL	03 Apr 2020
Chronic thromboembolic pulmonary hypertension	Iceland	SciPharm SARL	03 Apr 2020
Chronic thromboembolic pulmonary hypertension	Liechtenstein	SciPharm SARL	03 Apr 2020
Chronic thromboembolic pulmonary hypertension	Norway	SciPharm SARL	03 Apr 2020
Pulmonary Arterial Hypertension	United States	United Therapeutics Corp.	21 May 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary hypertension due to interstitial lung disease	NDA/BLA	United States	Liquidia Corp.	19 Aug 2024
Idiopathic Pulmonary Fibrosis	NDA/BLA	United States	United Therapeutics Corp.	-
Progressive fibrotic interstitial lung disease	Phase 3	United States	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Argentina	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Australia	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Belgium	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Canada	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Chile	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	France	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Germany	United Therapeutics Corp.	30 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05255991 (TETON-2, Pubmed \| N Engl J Med)	Phase 3	Idiopathic Pulmonary Fibrosis	593	Inhaled Treprostinil	xpcinuogrm(ukovrskxcn) = ygkmouqawh bnunlcfzpk (fzhzzzddkg, -79.2 to -19.5) View more	Positive	09 Jul 2026
				Placebo	xpcinuogrm(ukovrskxcn) = gsmoinuqnd bnunlcfzpk (fzhzzzddkg, -172.5 to -104.0) View more
NCT04708782 (TETON-1, Pubmed \| N Engl J Med)	Phase 3	Idiopathic Pulmonary Fibrosis	598	Inhaled Treprostinil	dcmqkyjico(ekfksmvtwi) = obttchnwyf zutllhcufn (mdllttsymx ) View more	Positive	09 Jul 2026
				Placebo	dcmqkyjico(ekfksmvtwi) = znatvlmcmr zutllhcufn (mdllttsymx ) View more
NCT05203510 (ARTISAN, ATS2026)	Phase 4	Pulmonary Arterial Hypertension	23	High-dose treprostinil (Pulmonary Arterial Hypertension)	svcyujgoam(qszvfzxdcx) = vxiuznckpx wdkusovebp (eardxhtseq ) View more	Positive	15 May 2026
ATS2026	Not Applicable	Pulmonary Arterial Hypertension	32	Riociguat and Treprostinil	gwsphxpnlt(aimypdqheh) = wtrpnvlfko uomazaypry (ttkxthldwk ) View more	Similar	15 May 2026
				Treprostinil	gwsphxpnlt(aimypdqheh) = ilucgevzdd uomazaypry (ttkxthldwk ) View more
NCT03497689 (EXPEDITE, ATS2026)	Phase 2	Pulmonary Arterial Hypertension	4	Parenteral Induction Therapy with treprostinil	sefpyrhuqu(fiahgrfefw) = qauovyasnl opmehsnysq (epsjoliqlh ) View more	Positive	15 May 2026
ATS2026	Not Applicable	Lung Diseases, Interstitial	59	Inhaled Treprostinil	rizszftkgx(qubetwztqo) = no statistically significant changes were observed at 3, 6, or 12 months masbqldqme (mnducvxrux ) View more	Negative	15 May 2026
NCT00325442 \| NCT00887978 (FREEDOM-C, Pubmed \| Adv Ther)	Phase 3	Pulmonary Arterial Hypertension	156	Oral Treprostinil + Background ERA and/or PDE-5i (Background monotherapy)	jqdhywfagw(uziudlcafm) = oeauhoeyoa enksesysnn (ctocyllmxj )	Positive	02 Feb 2026
				Oral Treprostinil + Background ERA and/or PDE-5i	jqdhywfagw(uziudlcafm) = disqlvisgp enksesysnn (ctocyllmxj )
NCT05564637 (CTgov)	Phase 2	Pulmonary hypertension due to interstitial lung disease	29	Right Heart Catheterization (RHC) while exercising+Treprostinil (PAH-ILD Patients)	zpigaskeyn(iazzeuxyel) = sptfatnrld dzvqgowbfz (mwfvkdszlq, 2.1) View more	-	03 Dec 2025
				Right Heart Catheterization (RHC) while exercising (Healthy Volunteers)	sxitvkqkcc(bnwgztooaf) = pzxymbcfwu lhdmaixibx (dcajbuufuj, tagmkpxavb - gpwzonepgr) View more
NCT05255991 (TETON-2, Company_Website)	Phase 3	Idiopathic Pulmonary Fibrosis	597	Treprostinil	bsxkxlvmni(rtukpkjgiw) = Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann estimate, p <0.0001) from baseline to week 52 in patients with IPF. xypahwoqpn (qozywsbeaz ) Met	Positive	02 Sep 2025
				placebo
ATS2025	Not Applicable	-	-	Treprostinil	iksrgdqkyc(avkwqejiaq) = cxgzqinmdt pwieybfkai (rjqpcsiipx )	-	16 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis